熱門資訊> 正文
Decoy Therapeutics获得350万美元PIPE融资;股价飙升
2026-06-29 21:09
- Decoy Therapeutics (DCOY) entered into a $3.5M PIPE financing with a single healthcare-focused institutional investor.
- The company will use the net proceeds to advance its lead antiviral candidate into clinical trials.
- The PIPE is priced at $5.91/share, with closing expected on or about June 29, 2026.
- The financing includes milestone-based warrants that could provide up to an additional $17.5M in gross proceeds upon achieving regulatory and clinical milestones.
- The milestone warrants are tied to Phase 1 CTA filing in Europe, Phase 2a trial approval in the UK, and positive Phase 2a trial data.
- DCOY shares up 116% premarket.
More on Salarius Pharmaceuticals
- Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript
- Seeking Alpha’s Quant Rating on Salarius Pharmaceuticals
- Financial information for Salarius Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。